Reports Q4 Cash, cash equivalents and marketable securities were $166.9M as of December 31 compared to cash and cash equivalents of $162.6M as of December 31 .Net loss was $7.6M or 4c per basic and diluted share, for the fourth quarter of 2022, compared to net income of $8.9M or 4c per basic and diluted share, for the same period in 2021.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SESN:
- Sesen Bio announces Glass Lewis recommendation to vote for merger with Carisma
- Sesen Bio boosts special cash dividend to 36c per share, Torok to join board
- Sesen Bio gets Nasdaq delisting notice, company sees Carisma deal as viable path
- Sesen Bio: Pending Carisma merger in best interests of stockholders
- Radoff and Torok urge Sesen Bio board to hold a stockholder vote soon
